182 related articles for article (PubMed ID: 22553340)
1. Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo.
Fransen S; Gupta S; Frantzell A; Petropoulos CJ; Huang W
J Virol; 2012 Jul; 86(13):7249-55. PubMed ID: 22553340
[TBL] [Abstract][Full Text] [Related]
2. Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir.
Huang W; Frantzell A; Fransen S; Petropoulos CJ
Antimicrob Agents Chemother; 2013 Sep; 57(9):4105-13. PubMed ID: 23733474
[TBL] [Abstract][Full Text] [Related]
3. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.
Fransen S; Gupta S; Danovich R; Hazuda D; Miller M; Witmer M; Petropoulos CJ; Huang W
J Virol; 2009 Nov; 83(22):11440-6. PubMed ID: 19759152
[TBL] [Abstract][Full Text] [Related]
4. G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.
Ni XJ; Delelis O; Charpentier C; Storto A; Collin G; Damond F; Descamps D; Mouscadet JF
Retrovirology; 2011 Aug; 8():68. PubMed ID: 21854605
[TBL] [Abstract][Full Text] [Related]
5. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.
Hassounah SA; Mesplède T; Quashie PK; Oliveira M; Sandstrom PA; Wainberg MA
J Virol; 2014 Sep; 88(17):9683-92. PubMed ID: 24920794
[TBL] [Abstract][Full Text] [Related]
6. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
[TBL] [Abstract][Full Text] [Related]
7. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
[TBL] [Abstract][Full Text] [Related]
8. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.
Delelis O; Thierry S; Subra F; Simon F; Malet I; Alloui C; Sayon S; Calvez V; Deprez E; Marcelin AG; Tchertanov L; Mouscadet JF
Antimicrob Agents Chemother; 2010 Jan; 54(1):491-501. PubMed ID: 19901095
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 Group O Resistance Against Integrase Inhibitors.
Depatureaux A; Mesplède T; Quashie P; Oliveira M; Moisi D; Plantier JC; Brenner B; Wainberg MA
J Acquir Immune Defic Syndr; 2015 Sep; 70(1):9-15. PubMed ID: 26017662
[TBL] [Abstract][Full Text] [Related]
10. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
Goethals O; Vos A; Van Ginderen M; Geluykens P; Smits V; Schols D; Hertogs K; Clayton R
Virology; 2010 Jul; 402(2):338-46. PubMed ID: 20421122
[TBL] [Abstract][Full Text] [Related]
11. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.
Canducci F; Marinozzi MC; Sampaolo M; Boeri E; Spagnuolo V; Gianotti N; Castagna A; Paolucci S; Baldanti F; Lazzarin A; Clementi M
J Antimicrob Chemother; 2010 Mar; 65(3):425-33. PubMed ID: 20056687
[TBL] [Abstract][Full Text] [Related]
12. Impact of the HIV integrase genetic context on the phenotypic expression and in vivo emergence of raltegravir resistance mutations.
Nguyen TT; Rato S; Molina JM; Clavel F; Delaugerre C; Mammano F
J Antimicrob Chemother; 2015 Mar; 70(3):731-8. PubMed ID: 25336162
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.
Métifiot M; Maddali K; Naumova A; Zhang X; Marchand C; Pommier Y
Biochemistry; 2010 May; 49(17):3715-22. PubMed ID: 20334344
[TBL] [Abstract][Full Text] [Related]
14. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.
Abram ME; Hluhanich RM; Goodman DD; Andreatta KN; Margot NA; Ye L; Niedziela-Majka A; Barnes TL; Novikov N; Chen X; Svarovskaia ES; McColl DJ; White KL; Miller MD
Antimicrob Agents Chemother; 2013 Jun; 57(6):2654-63. PubMed ID: 23529738
[TBL] [Abstract][Full Text] [Related]
15. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
Hu Z; Kuritzkes DR
J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
[TBL] [Abstract][Full Text] [Related]
16. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.
Hu Z; Kuritzkes DR
J Acquir Immune Defic Syndr; 2010 Oct; 55(2):148-55. PubMed ID: 20634701
[TBL] [Abstract][Full Text] [Related]
17. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
Stefic K; Salmona M; Capitao M; Splittgerber M; Maakaroun-Vermesse Z; Néré ML; Bernard L; Chaix ML; Barin F; Delaugerre C
J Antimicrob Chemother; 2017 Mar; 72(3):850-854. PubMed ID: 27999055
[TBL] [Abstract][Full Text] [Related]
18. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
[TBL] [Abstract][Full Text] [Related]
19. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.
Armenia D; Vandenbroucke I; Fabeni L; Van Marck H; Cento V; D'Arrigo R; Van Wesenbeeck L; Scopelliti F; Micheli V; Bruzzone B; Lo Caputo S; Aerssens J; Rizzardini G; Tozzi V; Narciso P; Antinori A; Stuyver L; Perno CF; Ceccherini-Silberstein F
J Infect Dis; 2012 Feb; 205(4):557-67. PubMed ID: 22238474
[TBL] [Abstract][Full Text] [Related]
20. Evolution of raltegravir resistance during therapy.
Sichtig N; Sierra S; Kaiser R; Däumer M; Reuter S; Schülter E; Altmann A; Fätkenheuer G; Dittmer U; Pfister H; Esser S
J Antimicrob Chemother; 2009 Jul; 64(1):25-32. PubMed ID: 19447792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]